

## Appendix H List of medicines to be included

This list refers to codes from BNF version 68.

Drug class (for this analysis)	BNF chapter	Drugs included
Opioids	4.7.2	Buprenorphine
		Codeine*
		Dextromoramide
		Diamorphine
		Dihydrocodeine**
		Dipipanone (including with cyclizine)
		Fentanyl
		Hydromorphone
		Meptazinol
		Methadone
		Morphine (including with cyclizine)
		Oxycodone (including with naloxone)
		Papaveretum
		Pentazocine
		Pentazocine
		Pethidine
		Tapentadol
		Tramadol (including with paracetamol)
		4.7.1
		Dihydrocodeine with paracetamol = co-dydramol**
Z-drugs	4.1.1	Zaleplon <sup>§</sup>
		Zopiclone
		Zolpidem
Benzodiazepines <sup>£</sup>	4.1.1 (insomnia)	Flurazepam
		Loprazolam
		Lormetazepam
		Nitrazepam
		Temazepam

<b>Drug class (for this analysis)</b>	<b>BNF chapter</b>	<b>Drugs included</b>
	4.1.2 (anxiety)	Diazepam
		Chlordiazepoxide
		Lorazepam
		Oxazepam
		Clonazepam
Gabapentinoids	4.7.3	Gabapentin
	4.8.1	Pregabalin
Antidepressants	4.3.1 (Tricyclics)	Amitriptyline (including with perphenazine)
		Amoxapine
		Clomipramine
		Dosulepin
		Doxepin
		Imipramine
		Lofepramine
		Maprotiline
		Mianserin
		Nortriptyline
		Protriptyline
		Trazodone
		Trimipramine
	4.3.2 (MAOIs)	Isocarboxazid
		Moclobemide
		Phenelzine
		Tranlycypromine
	4.3.3 (SSRIs)	Citalopram
		Escitalopram
		Fluoxetine
		Fluvoxamine
		Paroxetine
		Sertraline

Drug class (for this analysis)	BNF chapter	Drugs included
	4.3.4 (Other antidepressants)	Agomelatine
		Duloxetine
		Flupentixol
		Mirtazapine
		Nefazodone
		Oxipriptan
		Reboxetine
		Tryptophan
		Venlafaxine
		Vortioxetine

List of medicines taken from the 2019 Public Health England review of prescribed medicines, and adapted where necessary.<sup>341</sup>

\* Although they are captured within different BNF chapters, codeine and co-codamol will be regarded as a single drug when considering co-prescribing within the opioid class.

\*\* Although they are captured within different BNF chapters, dihydrocodeine and co-dydramol will be regarded as a single drug when considering co-prescribing within the opioid class.

§ Zaleplon was initially included for consistency with the Public Health England (PHE) report on prescribed drug dependence and withdrawal. Subsequent to starting guideline development, Zaleplon was discovered to no longer have a marketing authorisation in the UK. Therefore, it was excluded from evidence reviews.

£ Alprazolam and clobazam are listed within the BNF, however they are not prescribable in NHS primary care. Therefore, they were not included in this guideline. This is consistent with the Public Health England (PHE) report on prescribed drug dependence and withdrawal.